In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: VHA/Ethicon

This article was originally published in The Gray Sheet

Executive Summary

VHA/Ethicon: VHA combines previous supply pacts with Johnson & Johnson's Ethicon and Ethicon Endo-Surgery business into a single contract for supply of sutures and endoscopic instruments. The renewed agreement, which expires in June 2000, "will provide additional savings over the previous agreement," VHA says. VHA pursued a single agreement "because a survey of VHA members indicated that two-thirds of them would accept a committed agreement if it provided better discounts," the hospital group says. VHA recently announced plans to combine its supply chain management business with the University HealthSystem Consortium's supply operation. The combined entity is expected to renew an agreement with J&J when the current pact expires. UHC currently offers sutures and endoscopic instruments supplied by Sherwood, Davis & Geck and U.S. Surgical...

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

UsernamePublicRestriction

Register

MT009068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel